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The retention rate of the spin label 3-isothiocyanto methyl-2,2,5,5-tetramethyl-l-pyrrolidinyl oxyl
spin label (proxyl) attached to the porcine N-acetyl-NPY peptide and the porcine N-acetyl-D-Trp32-
NPY peptide at Lys4 was investigated using SK-N-MC neuroblastoma cell membranes containing
the Yl receptor. The release rate of the spin labeled peptides was monitored by electron spin
resonance and the KD was determined by a direct radiolabeled NPY displacement binding assay.
The analyses show that for the porcine [Ac-Tyr'NE4-proxyl]-NPY, the KD was 8 X 10
-10 M and
koff was 2.7 X 10
-4 sec-1 yielding a value for kon of 3.3 X 10
5 sec-1 M-1. The [Ac-Tyr1, NE4-
proxyl,-D-Trp32]-NPY antagonist ligand had a value of KD equal to 1.35 X 10
-7 M and koff was
1.7 X 10-4 sec-1 leading to a value for kon of 1.2 X 10
3 sec-1 M-1. The difference in the kon rates
of two orders of magnitude is interpreted as demonstrating the N-acetyl-Ne4 proxyl-D-Trp32-NPY
ligand binding transition state to be of higher energy then for the unmodified NPY amino acid
sequence.
KEY WORDS: NPY binding; on and off rates, NPY agonist and antagonist binding; activation energy dif-
ference in receptor binding.
INTRODUCTION
Neuropeptide Y (NPY) is a 36 amino acid peptide
that is widely distributed in both the central nervous sys-
tem (CNS) and the peripheral nervous system (PNS).
Among the many biological activities in the CNS that
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have been attributed to this peptide are stimulation of
appetite activity (1), regulation of circadian rhythm ac-
tivity (2), modulation of body temperature, and induc-
tion of catalepsy (3), and effects on memory processing
(4). In the PNS the NPY ligand in conjunction with nor-
adrenalin is reported to function as a regulator of vas-
cular tone (5). The isolation of Neuropeptide Y from
porcine brain was reported by Tatemoto (6,7) who noted
that it bore a close primary structure analogy to avian
pancreatic polypeptide (APP) (6) and to porcine pancre-
atic polypeptide. NPY has a primary structure homology
to peptide YY (PYY) of about 69% (8) and to porcine
polypeptide of about 50% homology (9). Since 1982 a
number of NPY's from other species have been isolated
and sequenced, and a large number of NPY analogs have
been synthesized and evaluated with respect to biologi-
cal activity and receptor binding behavior (10).
0364-3190/97/0400-0437$12.50/0 © 1997 Plenum Publishing Corporation
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The secondary and tertiary structures of NPY have
been investigated using circular dichroism and NMR,
and a 3D model has been proposed from these studies
(11,12,13). The x-ray structure of the homologous pep-
tide APP, has been reported (14); however, to date nei-
ther the parent peptide nor any analogs have been
crystallized. This may, in part, be attributed to a more
flexible N-terminal structure than the N-terminal struc-
ture of APP (15). There are three known NPY receptor
subtypes which have been designated as Y1, Y2, and Y3
(16). The human and rat Y receptor genes have been
cloned and sequenced (17,18,19) and permit the char-
acterization of the Y! receptor as a G protein coupled
receptor that mediates the inhibition of cyclic AMP in
some cell types and is coupled to the elevation of intra-
cellular calcium in other cell types. The length of time
that a neuropeptide is retained by its G-protein coupled
receptor component is an essential parameter in the elu-
cidation of the time sequence in G-protein signal trans-
duction. Neuropeptide Y and its receptor linked G
protein signal transduction system can be used to accu-
rately determine the residence time of the ligand to its
receptor using spin labeled ligands. The report by Bal-
asubramaniam et al. (20) that D-Trp32-NPY was a com-
petitive antagonist of NPY suggested a series of
experiments to measure the retention time of the NPY
ligand and the D-Trp32 NPY ligand, by the Y, receptor
in the SK-N-MC cell membrane. The SK-N-MC cell line
is reported to selectively express the number of Y, re-
ceptors as between ~ 85,000 (21) and 200,000 receptors
per cell, with a KD ~ 2nM, almost to the exclusion of
the other Y type receptors, (22,23). Our search of the
literature has not found any report for the on or off rates
of NPY binding to its receptor. Using the epr technique
to measure the off rate allows for immediate monitoring
of the amount of ligand bound and free when the starting
point begins with 100 percent bound ligand. We have
synthesized spin labeled porcine NPY and porcine D-
Trp32 NPY in order to determine their respective on/off
binding properties to the NPY receptor in the SK-N-MC
cell membrane.
The amino acid sequence for the porcine NPY is
shown below and differs from human NPY only in the
substitution of a leucine residue for a methionine residue
at position 17.
SEQUENCE for porcine N-Acetyl NPY
Ac-Y-P-S-K-P-D-N-P-G-E-D-A-P-A-E-D-L-A-R-Y-Y-
S-A-L-R-H-Y-I-N-L-I-T-R-Q-R-Y-NH2
SEQUENCE for porcine N-Acetyl-D-Trp32-NPY
Ac-Y-P-S-K-P-D-N-P-G-E-D-A-P-A-E-D-L-A-R-Y-Y-
S-A-L-R-H-Y-I-N-L-I-oW-R-Q-R-Y-NH2
The proxyl spin label was attached to the lysine residue
We report the first determinations for the on/off rate of
spin labeled NPY and D32Trp NPY with respective bind-
ing constants similar to the binding constants for the
untagged NPY's.
EXPERIMENTAL PROCEDURE
Synthesis of NPY and oTrp12 NPY. Typical peptide synthesis was
carried out using Rink amide resin (0.25mmol, 0.5 g) and the stepwise
coupling of Fmoc amino acids using an Applied Biosystems model
431A peptide synthesizer.
Acetylation of NPY and [oTrp32]NPY and Cleavage from the
Resin. The peptide, while still attached to the resin (0.30g), was treated
with 10 ml of NMP, 1.0 ml of pyridine and 1 ml of acetic anhydride.
The suspension was shaken at room temperature for 30 minutes and
then drained. After an initial washing with NMP and then with dicho-
loromethane, the N-acetylated peptide attached to the resin was treated
with 0.5 ml of thioanisole, 0.5 ml of EDT and 10 ml of 95% trifluo-
roacetic acid for 3 hours. After filtering, the residual resin was sub-
jected to an additional wash with 1.0 ml of 95% TFA, and the
combined washings and filtrate concentrated in vacuo to yield an oil
which was then triturated with diethyl ether to give 0.14 g of crude
peptide.
Attachment of the Spin Label 3-Isothiocyanto Methyl-2,2,5,5-Te-
tramethyl-1-Pyrrolidinyl Oxyl to the Peptide at Lys-4. Crude peptide
(0.020 g) was dissolved in 1.0 ml of an H2O/CH3CN (1:1 v/v) mixture
and this solution was then adjusted to pH 9.0 with saturated NaHCO3
solution. A solution of 5.7 mg of the spin label dissolved in 0.1ml of
NMP was added to the peptide solution. The progress of the reaction
was monitored periodically, and after 4 hours an additional 6.0 mg of
the spin label reagent was added to the reaction. The reaction appeared
to be complete after 6.5 hours. The mixture was subjected to HPLC
on a Vydac C18 reversed phase preparative column and eluted with a
H2O/CH3CN gradient containing 0.1% TFA. Amino acid analysis and
electrospray mass spectroscopy on each of the purified peptides were
in excellent agreement with the predicted values.
Preparation of Cells and Cell Membranes. Human neuroblastoma
cells, SK-N-MC, obtained from American Type Culture Collection
(Cat. No. HTP10) were grown in Dulbecco's modified Eagle medium
(Gibco) containing 10% fetal bovine serum and 100 units per
ml/lOOag per ml, penicillin/streptomycin (Gibco). After confluence the
cells were fed and incubated at 37°C for an additional 24 hrs. The
growth medium was removed, and the cells are then rinsed in a buffer
consisting of: 25 mM Tris, pH7.4, 6 mM MgCl2, 250ug/ml bacitracin,
250 ng/ml aprotinin, 250 ug/ml leupeptin, 250 ug/ml Peflabloc, (Pen-
Structure 1.
at position four in the peptide chain using the isothio-
cyanate derivative of the proxyl compound, Structure 1.
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tapharm AG). The cells were lifted from the flasks with Dulbecco's
phosphate buffered saline solution (PBS) containing 0.02% EDTA.
Cells were pelleted and homogenized using a polytron and the broken
cell membranes were centrifuged at 18,000 rpm for 10 min. at 4°C.
The pelleted membranes were resuspended in the TRJS buffer and
frozen at -70°C.
Binding Assay Protocol. Dulbecco-PBS (Gibco) pH 7.4 containing
0.5 g/1 bacitracin and 1 g/1 BSA was used in the preparation of all assay
components. Each assay tube consisted of the following: 100 |ll of var-
ied concentrations of [Ac-Tyr1Ne4-proxyl]-NPY or [Ac-Tyr1, Ne4-proxyl,-
D-Trp32]-NPY or buffer, 100 ul of a solution of porcine 125I-PYY
(30pmoles/tube) and 50 ul of SK-N-MC membrane preparation contain-
ing 50 ul/tube of protein for a total volume of 250 ul per tube. Non-
specific binding was determined by the addition of excess cold
neuropeptide Y (300 nM). After the addition of all the reagents, the
tubes were shaken while incubating for sixty minutes at room temper-
ature. The assay was terminated by filtering the suspension through a
Whitman GF/C glass filter pad previously saturated with 0.1% polyeth-
ylene imine in 10 mM Tris, pH 7.5 containing 0.1% BSA. The filters
were punched from the filter mat and counted for 1 min.
In the binding protocol the radioiodinated NPY ligand concentra-
tion was well below the value of KD. A concentration of 1 nM is
required to saturate all of the receptors. In this binding assay the ra-
dioligand concentration is such that no more than 10 percent of the
radioligand is bound, insuring that the radioligand concentration is not
rate limiting. The assay is carried out under equilibrium conditions in
which the membranes, radioligand, and different concentrations of
cold ligand are maintained at constant temperature for 1 hr and then
the amount of bound radiolabel is determined as a function of cold
ligand concentration. A plot of percent bound radiolabel against the
concentration of cold ligand yields the IC50 and this is taken as the
value of Ki which is equal to the binding constant KD, as derived by
Cheng and Prusoff, (24).
Spin Labeling Methods. The [Ac-Tyr1Ne4-proxyl]-NPY, and the
[Ac-Tyr1,N£4-proxyl,-D-Trp32]-NPY were dissolved in 1-2 drops of
DMSO and then diluted with Dulbecco's modified Eagle Medium
(GIBCO BRL') to 6 uM and 20 uM, respectively, the final concentra-
tion depending on the signal to noise ratio of the probe's epr signal.
Fifty mg of frozen membrane prepared from SK-N-MC cells was
centrifuged at 4000 rpm for 5 to 10 seconds in an Eppendorf centri-
fuge. One ml of ice cold spin label solution was added to the mem-
brane pellet which was resuspended and incubated on ice for 15
minutes. The suspension was centrifuged for 10 seconds, the spin
probe solution decanted and 1.0 ml of ice cold phosphate buffered
saline (PBS, GIBCO, BRL, with calcium) was added and the mem-
branes resuspended by light vortexing. The suspension was centrifuged
and cold rinsed two more times before being resuspended in 60-80 ul
of PBS and loaded at room temperature into the flat epr cell (~100
ul volume) for epr measurement.
Two to three T-150 flasks containing 20-30 x 106 SK-N-MC cell
monolayers were used for each epr measurement. Two mM
KCN/iodoacetamide in Dulbecco's medium containing 10% fetal calf
serum was added to the monolayers to inhibit oxidative metabolism
and the cells kept on ice for 2 hours. The medium was decanted, the
monolayers rinsed three times with cold PBS and the cells scraped
using a Costar cell scraper. The cells were centrifuged and resus-
pended in 1.0 ml of the spin label medium (ice cold). After 15 minutes
incubation on ice, the cells were centrifuged and washed three times
with cold PBS. The cells were resuspended in 200 ul and 100 u1 was
loaded into the flat cells for epr measurement.
EPR Measurement. The membrane pellet is transferred to an epr
flat cell (W6-808-Q, Wilmad, Buena, NJ) for data collection. The epr
protocol requires that the data be collected as 4X1-minute-sweep spec-
tra, the acquisitions being separated to provide a time evolution of the
spectral features. Typically, the evolution of the spectra is complete
in an hour. The data are collected in a signal averager (Model NS-
900, TRACOR/Northern, Middleton, WI) at 37°C, 5 mW incident mi-
crowave power, and 0.08 mT field modulation, 9.174 GHz microwave
frequency. The data are reduced to five parameters using previously
developed software that determines the g- and a-values and the three
linewidths appropriate to each spectrum.
The linewidth values are converted to relative concentrations by
establishing the ratios of bound-to-free labeled ligand. The linewidths
of the free ligand at 37°C (0.097, 0.095 and 0.109 mT) were deter-
mined by obtaining the spectrum of dissolved spin labeled ligand in
buffer and computer simulating the epr signal. The linewidths of the
bound ligand (0.155, 0.130, 0.256 mT) were determined by trial ex-
periments where membrane samples were exposed to labeled ligand,
and then their epr spectra were obtained in the shortest possible time
(~2 minutes after warming the sample to 37°C). The linewidths of the
bound label and the free label did not differ sufficiently to prevent the
use of Lorentzian lineshapes to approximate the lineshape of a sample
containing both bound and free label.
To use the Lorentzian lineshape approximation, we need to cal-
culate the observed lineshape of the spectral resonance that is the sum
of two different lineshapes. The component lineshapes are assumed to
be Lorentzians and functions of the variable x, which is zero at the
center of the resonance. If we assume that the free label has linewidth,
r,, and maximum intensity equal to one, and that the bound label has
linewidth, T2, and maximum intensity equal to a, then the composite
lineshape will have a maximum equal to 1 + a at x = 0. The linewidth
of the sum of these two lineshapes can be approximated by finding
the point where the composite lineshape is at half maximum. To find
that value, the following expression should be solved for x:
If we make the approximation that the solution of Eqn. 1 is the line-
width of the composite lineshape, F3, then
The value of (a) is calculated as the average from that derived from
the three linewidths. The per cent bound label, B, is given by
By computer simulating trial lineshapes and then fitting these simu-
lations, we have determined the error inherent in this data reduction
method (in the absence of noise). The standard error of B (over its
entire range from zero to 100) is 1.5%, with the maximum error (4.1%)
occurring at B equal to 66%.
RESULTS AND DISCUSSION
The ability of Neuropeptide Y to elicit its diverse
physiological effects derives from its actions as a ligand
for its G protein coupled receptor. The biochemical con-
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Fig. 1. Epr spectrum of unbound proxyl-NPY at 37°C. These data
(solid line) are typical for the unbound spin labeled peptide (see Fig
2B) and are superimposed by a computer simulation (dashed line),
which is based on five parameters: the a- and g-values and the three
Lorentzian linewidths.
sequence of this ligand receptor binding is the inhibition
of adenylate cyclase since the G protein coupled to this
receptor is a G, subtype (10). The receptor itself is
known to be a seven helix bundle but the locus of the
binding site and the forces involved in the binding are
yet to be elucidated. No significant change in the binding
constant was found when a proxyl spin label was co-
valently attached to the e-amino group of the lysine res-
idue at position 4 in the NPY peptide. Since the
determination of the binding constant is not done by the
determination of the equilibrium concentrations of the
species involved, but rather by the displacement of a
bound radioactive PYY ligand, the constant that is de-
termined is therefore equivalent to an inhibition con-
stant. The relationship of K, to I50 for a system that
appears to obey Michaelis-Menten or Langmuir adsorp-
tion was reported in 1973 by Cheng and Prusoff(24).
Their derivation shows that for bisubstrate competitive
or noncompetitive inhibition, I50 = Ki provided that the
affinity of the inhibitor for the free receptor is the same
as that for the receptor ligand complex. The constant for
[Ac-Tyr'NE4-proxyl]-NPY, was determined to be 8.0 X
10-10 M [0.8 nM]. In contrast to this finding, the sub-
stitution of a D-tryptophan residue at position 32 in the
NPY sequence containing the spin label, resulted in a
constant of 1.35 X 10-7 M [135 nM].
Although the derivation for the calculation of the
binding constant is based upon a kinetic argument, the
constant is inherently an expression of an equilibrium
condition. One approach to the derivation of the law of
mass action is based on a kinetic argument and, there-
fore, it is considered valid to develop the following ex-
pression that relates the binding constant to the on and
where K i is taken as equivalent to the binding constant
KD.
Figure 1 shows the epr spectrum of unbound NPY
containing the spin label. The cells were incubated at
4°C for 15 minutes, cold rinsed and cenrrifuged three
times, and then transferred to the epr flat cell and placed
in the spectrometer at 37°C for spectral acquisition. If
the ligand did not dissociate at 4°C then the appropriate
onset for the dissociation of the ligand would be close
to 18 minutes, in agreement with our extrapolated values
of 12 and 19 minutes. The spin-labeled neuropeptides
were added to SK-N-MC cell membrane preparations,
Fig. 2, to determine the ratio of bound to free spin-la-
beled neuropeptide. The percent bound neuropeptide Y
was then fit by a linear regression to establish the rate
of release. The above procedure was repeated for the D-
Trp peptide (representative data shown in Fig. 3). Fig.
2 and 3 reveal that the effects of ligand binding on the
epr linewidth are subtle and difficult to see because of
the spectral noise. Nevertheless, the graphs in Fig. 4
demonstrate that these effects are measurable and repro-
ducible. Analysis of the epr data showed that the label
was slowly released at different rates for the two ligand
molecules. The data indicates that the antagonist neu-
ropeptide with a D-tryptophan residue at position 32 was
released at a rate of 1.0 per cent per minute (koff =1 .7
X 10-4 sec-1) from the receptor while the unmodified
neuropeptide Y was released at the rate of 1.6 per cent
per minute (koff = 2.7 X 10
-4 sec-1). The R values for
these two regression lines are modest: 0.94 for the D-
trp32 containing peptide and 0.72 for the native peptide.
On the other hand, the regression lines can be extended
back to the point where they equaled 100 per cent bound
label. By solving these regression lines for B = 100 per
cent, we obtain 19 minutes for the D-trp32 peptide ligand
and 12 minutes for the start of the native ligand. These
numbers are in good agreement with the value of 18 ±
1 minutes, the time that the spin label and membranes
were mixed, kept at 4°C, and warmed from their incu-
bation temperature of 4°C. Both the reproducibility and
the fact that these data were able to successfully extrap-
olate to the beginning of the experiment give us confi-
and the value for kon can be calculated from the rela-
tionship
off rate constants of the ligands.
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[Ac-Tyr1, Ne4-proxyl,-D-Trp32]-NPY it was 1.2 X 103
sec-1 M-1. There is a large difference in the binding
rates of the two neuropeptides. Because these molecuJes
resemble one another in terms of size, solubility and
structure, we would have expected the "on rates" to be
very similar. The fact that they are not similar is inter-
preted by us to signify that the binding transition state
(in the sense of a transition state theory model) is lower
in energy for the [Ac-Tyr1Ne4-proxyl]-NPY ligand than
for the [Ac-Tyr1Ne4-proxyl,-D-Trp32]-NPY molecule.
Therefore the effect of substituting D-Trp32 for L-Thr32
is to make it more difficult to pass through this transition
state in the binding of the neuropeptide. This interpre-
tation contrasts with the possible experimental alterna-
tive result where the on-rates are equal, signifying that
Fig. 3. Epr spectrum of d-Trp32-proxyl-NPY labeled SK-N-MC mem-
branes at 37°C. These data are scaled so that each is proportional to
the recorded amplitudes. The linewidths become narrower as a func-
tion of time. The times from the initial mixing of the receptors and
the spin label to the halfway point of the sample acquisitions are: A)
23 min., B) 27 min., C) 34 min., and D) 45 min.
Fig. 2. Epr spectrum of proxyl-NPY labeled SK-N-MC membranes at
37°C. These data are scaled so that each is proportional to the recorded
amplitudes. The linewidths become narrower as a function of time.
The times from the initial mixing of the receptors and the spin label
to the halfway point of the sample acquisitions are: A) 23 min., B) 27
min., C) 34 min., and D) 45 min.
dence in the accuracy of the slopes of these regression
lines, which are their only parameters relevant to the
binding of the neuropeptide. These results are interpreted
to mean that the neuropeptides were released by the re-
ceptor into the solution at this rate. Chemical modifica-
tion would produce an altered epr spectrum and this was
not seen. The epr spectra of the labeled membranes, after
one hour at 37°C, had changed to a spectrum identical
to that of the spin labeled neuropeptide dissolved in wa-
ter.
Because these epr results provide the "off rates"
for the previously measured binding constants, the "on
rates" for binding are calculable by dividing the "off
rates" by the K i's. The value obtained for kon for [Ac-
Tyr1Ne4proxyl]-NPY, was 3.3 X 105 sec-1 M-1 and for
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Fig. 4. Percent of the bound spin label as a function of time after
mixing the labeled neuropeptides with the SK-N-MC membranes, su-
perimposed by their regression lines. The regression equations were:
B = 120-1.04T (R = 0.94) for the D-Trp32 containing peptide (A) and
B = 118-1.56T (R = 0.72) for the unmodified NPY. The regression
lines are extended back in time (dashed portion) to where they equal
100 on the ordinate.
the transition state has the same energy for both NPY
and D-Trp32-NPY molecules. In this case the differences
in binding would have to manifest themselves in vastly
different neuropeptide off rates.
Spin label experiments were also performed on the
SK-N-MC cell suspensions. Unfortunately, these exper-
iments were not successful in determining the bound to
free ratios of the spin-labeled neuropeptides because the
spin-label was chemically reduced, annihilating the ni-
troxide signal by the cellular metabolic chemistry before
a significant change in the epr linewidth could be mea-
sured. In our experience, most living cells at 37°C will
use the dissolved oxygen in the cell slurry within five to
ten minutes after they are added to the flat cell. The time
depends on the thickness of the cell slurry. At this point,
the reducing excess in the cells resulting from the an-
aerobic conditions begins to chemically reduce the ni-
troxide spin label. The epr signal can be recovered by
aeration of the sample, proving that the loss of the signal
is due to chemical reduction. The result of this chemistry
is that the signal will disappear before the labeled pep-
tide comes off of the cell receptor. It was not possible
to poison the enzymatic pathways and inhibit this re-
duction, although cyanide and iodoacetamide were
added to the cell suspension in an attempt to block the
reductive pathways involving heme proteins. Rather than
attempting to inhibit the complex of reactions that could
be contributing to the reduction of the spin label, we
simply abandoned the intact cell experiments in favor of
experiments using membrane preparations.
This study indicates that the L-threonine to o-tryp-
tophan substitution of residue 32 of NPY greatly desta-
bilizes the transition state for binding of this ligand to
the Y, receptor. Thus, for these ligands binding to the
receptor, there may be a "guidance system" that allows
the ligand to bind to intermediate locations before it
reaches the ultimate binding site. For small flexible mol-
ecules binding to proteins it has been suggested that such
molecules change their conformation on binding. Fur-
thermore, the bound conformation may be considerably
above the global energy minimum (Nicklaus 1995). If
this hypothesis is valid for small flexible molecules bind-
ing to proteins, it should certainly be valid in the case
of the even more flexible small peptides binding to a
protein receptor and provides additional support for the
validity of our analysis of NPY and D-Trp NPY binding
to the Y, receptor.
If these ligands are "strained" in the binding pro-
cess, then the lessening of this strain becomes an attrac-
tive mechanism for the promotion of the binding. This
interpretation is consistent with our results and suggests
that the substitution of a D-trp at residue 32 is in accord
with such a mechanism in its binding behavior.
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